Keymed Biosciences Co.Ltd: Dermatitis, Atopic trials
The registry lists 18 Dermatitis, Atopic studies with Keymed Biosciences Co.Ltd as lead sponsor. 4 are open to participants now and 0 have results posted.
Phase 1 4Phase 2 12Phase 3 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.RecruitingNCT07230483Phase 2
- A Study of Stapokibatrt in Children Subjects With Atopic DermatitisNot yet recruitingNCT07106372Phase 3
- Study of Stapokibatrt in Children Subjects With Atopic DermatitisNot yet recruitingNCT06956196Phase 3
- Study of CM512 in Patients With Moderate-to-Severe Atopic DermatitisRecruitingNCT06947980Phase 2
- Study of CM512 in Healthy Subjects and Patients With Atopic DermatitisCompletedNCT06553209Phase 1
- Study of CM310 in Adolescent Subjects With Atopic DermatisActive, not recruitingNCT06495229Phase 3
- Study of CM310 Injection in Adolescent Subjects With Atopic DermatisCompletedNCT06277765Phase 3
- Study of CM310 in Children Subjects With Moderate-to-severe Atopic DermatisCompletedNCT06162507Phase 1/2
- A Study of CM310 in Subjects With Moderate-to-Severe Atopic DermatitisCompletedNCT06116565Phase 2
- Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic DermatitisCompletedNCT05715320Phase 2
- The Study of CM326 in Adult Subjects With Atopic DermatitisStatus unknownNCT05671445Phase 2
- The Study of CM326 in Moderate-to-severe Atopic DermatitisStatus unknownNCT05671432Phase 2
- A Study of CM310 in Children Patients With Moderate-to-severe Atopic DermatisCompletedNCT05579925Phase 2
- A Study of CM310 in Patients With Moderate-to-Severe Atopic DermatitisCompletedNCT05265923Phase 3
- The Study of CM326 in Patients With Moderate-to-severe Atopic DermatitisStatus unknownNCT05186922Phase 1/2
- Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)CompletedNCT04893941Phase 1/2
- The Study of CM310 in Patients With Atopic DermatitisCompletedNCT04893707Phase 2
- Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)CompletedNCT04805411Phase 2